Skip to main content

Table 4 Clinical outcomes of patients with viral pneumonia according to empiric antibacterial therapy

From: Impact of antibacterials on subsequent resistance and clinical outcomes in adult patients with viral pneumonia: an opportunity for stewardship

  Long course Short course Mixed infection
(n = 67) (n = 28) (n = 79)
Instances of subsequent MDRO infection or colonization 25/47 (53.2) 4/19 (21.1)* 20/53 (37.7)
 MRSA colonization 2/10 (20) 0/7 (0) 3/15 (20)
 VRE colonization 3/6 (50) 1/4 (25) 9/20 (45)
 MDRO infection 20/31 (64.5) 3/8 (37.5) 8/18 (44.4)
Patients with subsequent MDRO infection or colonization 16 (23.9) 3 (10.7) 16 (20.3)
 MRSA colonization 2 (3.0) 0 (0) 3 (3.8)
 VRE colonization 3 (4.5) 1 (3.6) 9 (11.4)
 MDRO infection 13 (19.4) 3 (10.7) 7 (8.9)
Subsequent Clostridium difficile infection 1 (1.5) 0 (0) 2 (2.5)
In-hospital mortality 8 (11.9) 3 (10.7) 23 (29.1)**
 Non-ICU 1/23 (4.3) 0/11 (0) 0/16 (0)
 ICU (all) 7/44 (15.9) 3/17 (17.6) 23/63 (36.5)**
 ICU – oncology 4/18 (22.2) 2/5 (40) 10/16 (62.5)**
 ICU – nononcology 3/26 (11.5) 1/12 (8.3) 13/47 (27.7)
Hospital LOS (days) 11 (7–25) 8.5 (5–20) 17 (8.5-28) ***
ICU LOS (days) 8.1 (4.9-17.9) 4.2 (2.8-14.7)* 12 (5.1-19.1) ***
Readmit within
 30 days 14 (20.9) 4 (12.9) 19 (24.0)
 90 days 22 (32.8) 8 (25.8) 27 (48.2)
 180 days 30 (44.8) 11 (35.5) 29 (51.8)
  1. Data expressed as number (% of total) or median (interquartile range)
  2. LOS length of stay, MDRO multidrug-resistant organism, MRSA methicillin-resistant Staphylococcus aureus, VRE vancomycin-resistant enterococci
  3. *Statistically significant difference (P <0.05) between short-course and long-course groups
  4. **Statistically significant difference (P <0.05) between long-course and mixed-infection groups
  5. ***Statistically significant difference (P <0.05) between short-course and mixed-infection groups